Recent trends in use of adjuvant chemotherapy in elderly stage II-III non-small cell lung cancer.

ABSTRACT:

Background

Although randomized trials demonstrated survival benefit of adjuvant chemotherapy, previous reports have suggested that its use in elderly populations for early stage non-small cell lung cancer (NSCLC) was infrequent. The current status of adjuvant chemotherapy in this population is unknown.

Methods

Using the Surveillance, Epidemiology, and End Results (SEER) database, we examined the incidence of chemotherapy in resected stage II-III NSCLC between 2004 and 2015. Staging was determined according to the American Joint Committee on Cancer (AJCC) 6th version. Cases were grouped by age (20-69, 70-79, and 80+). Trends in use of chemotherapy by age group were assessed by univariate and multivariate analyses.

Results

A total of 35,009 cases were selected as surgic

SUBMITTER: Komiya T 

PROVIDER: S-EPMC7481576 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature